Work Package 2

Work Package 2: Pre-clinical Imaging

Work Package 2 aims to:

  • provide a detailed understanding of the relationship between the fluoro-L-thymidine (FLT) positron emission tomography (PET) radiotracer pharmacokinetics, diffusion of water molecules – and pathology, allowing a better understanding of confounds of measurement;
  • provide information on effect size, dose-response and timing of therapy on apparent diffusion coefficient (ADC) magnetic resonance imaging (MRI) and FLT PET that will influence trial design of licensed drugs in Work Package 3;
  • provide a detailed understanding of the relationship between ICMT-11 radiotracer pharmacokinetics and pathology, allowing a better understanding of confounds of measurement;
  • provide information on effect size, dose-response, and timing of therapy on ICMT-11 that will influence trial design of licensed drugs in Work Package 3;
  • extend current knowledge on proliferation, apoptosis, and ADC MRI to novel pharmacologies and possibly to alternative imaging biomarkers.

Participating QuIC-ConCePT partners:

  1. AstraZeneca AB, Sweden
  2. Cambridge Research Institute, CR-UK, United Kingdom
  3. European Institute for Molecular Imaging at the Westfaelische Wilhelms-Universitaet Muenster, Germany
  4. Radboud University Nijmegen Medical Center, The Netherlands
  5. Université Paris Diderot, INSERM, France
  6. Imperial College London, United Kingdom
  7. Merck KgAA, Germany
  8. Sanofi-Aventis R&D, France

 

 

IMI oncology projects